Global Cancer Monoclonal Antibody Partnering Deal Trends, Players and Financials 2010-2016

Mar 16, 2016, 12:10 ET from Research and Markets

DUBLIN, March 16, 2016 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/jftnrw/global_cancer) has announced the addition of the "Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2010-2016: Deal trends, players and financials" report to their offering.

The Global Cancer Monoclonal Antibody Partnering 2010-2016: Deal trends, players, financials and forecasts report provides an understanding and access to the cancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare companies.

This report provides details of the latest antibody agreements announced in the healthcare sectors, covering:

  • Monoclonal antibodies
  • Murine mAb
  • Chimeric mAb
  • Humanized mAb
  • Human aAb

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not. that's the thing, don't know

Cancer Monoclonal Antibody Partnering Terms & Agreements includes:

  • Trends in cancer monoclonal antibody dealmaking in the biopharma industry since 2010
  • Analysis of cancer monoclonal antibody deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to over 360 cancer monoclonal antibody deal records
  • The leading cancer monoclonal antibody deals by value since 2010

In Cancer Monoclonal Antibody Partnering Terms & Agreements, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific oncology therapy target
  • Monoclonal antibody type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Cancer monoclonal antibody dealmaking

Chapter 3 - Leading Cancer monoclonal antibody deals

Chapter 4 - Most active Cancer monoclonal antibody dealmakers

Chapter 5 - Cancer monoclonal antibody contracts dealmaking directory

Chapter 6 - Cancer monoclonal antibody dealmaking by technology type

Chapter 7 - Partnering resource center

For more information visit http://www.researchandmarkets.com/research/jftnrw/global_cancer

Media Contact:

Research and Markets

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

 

SOURCE Research and Markets



RELATED LINKS

http://www.researchandmarkets.com